文献速递消化道肿瘤与早癌

SOX9驱动SPEM细胞谱系可塑性促进胃癌发生

SRY-Box 9-Driven Spasmolytic Polypeptide-Expressing Metaplasia Cell Lineage Plasticity Is a Potential Therapeutic Target That Mitigates Risk of Metaplastic Progression to Gastric Cancer.
PubMed 文献 · Gastroenterology · 2026-07-14

该研究利用两种Sox9敲除小鼠模型、单细胞RNA测序、人组织芯片及SPEM类器官,发现SOX9在主细胞向SPEM细胞转分化中起核心作用。Sox9敲除导致急慢性损伤后化生无法形成,并阻断化生向胃癌进展,鉴定出表达DNA拓扑异构酶II-α的SPEM亚群参与化生进展。

要点

  • SOX9是SPEM细胞谱系演化和化生进展的主调控因子
  • 主细胞中Sox9敲除使急慢性损伤后化生形成失败
  • SOX9介导的SPEM细胞可塑性是胃癌发生的关键机制

核心结论

  • SOX9是SPEM细胞谱系演化和化生进展的主调控因子。
  • SOX9介导的SPEM细胞可塑性是胃癌发生的中心机制。

研究设计与样本

  • 使用两种Sox9敲除小鼠模型:GCS(GIFrtTA/+;TetO-CreTg/+;Sox9flox/flox)和GCKS(GIFrtTA/+;TetO-CreTg/+;LSL-KrasG12DTg/+;Sox9flox/flox)。
  • 通过免疫荧光和单细胞RNA测序分析黏膜损伤后化生发展及癌变过程。
  • 在人患者组织芯片中验证发现,并使用SPEM类器官鉴定SOX9调控基因。

主要发现

  • 主细胞中Sox9敲除导致急性和慢性损伤后化生发展失败,主细胞无法转分化为SPEM细胞。
  • GCKS小鼠因缺乏负责化生进展和成纤维细胞募集至腺体底部的SPEM细胞亚群而无法进展通过癌变过程。
  • 腺体内重新填充了稳态胃细胞谱系。
  • 鉴定出表达DNA拓扑异构酶II-α的SPEM细胞亚群参与化生进展,并发现与谱系可塑性相关的 putative SOX9下游基因。

临床怎么用

  • SOX9介导的SPEM细胞可塑性可作为减轻化生向胃癌进展风险的潜在治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Gastric cancer develops through a sequential carcinogenic process beginning with pyloric metaplasia, a key feature of which is the transdifferentiation of gastric chief cells into spasmolytic polypeptide-expressing metaplastic (SPEM) cells. We found that SRY-Box 9 (SOX9), a transcription factor, is highly expressed in SPEM cells in both human and murine metaplasia. We therefore investigated the impact of SOX9-mediated SPEM cell plasticity and function on metaplasia development and progression during gastric carcinogenesis. METHODS: We used 2 Sox9 knockout mouse models, GIFrtTA/+;TetO-CreTg/+;Sox9flox/flox (GCS) and GIFrtTA/+;TetO-CreTg/+;LSL-KrasG12DTg/+;Sox9flox/flox (GCKS) to examine the effects of SOX9 loss on metaplasia development after mucosal injury and carcinogenesis by immunofluorescence and single-cell RNA sequencing. We also confirmed our findings in human patient tissue microarrays and used SPEM organoids to identify genes regulated by SOX9. RESULTS: Sox9 knockout in chief cells resulted in the failure of metaplasia development in both acute and chronic injury because chief cells were unable to transdifferentiate into SPEM cells. The GCKS mouse failed to progress through carcinogenesis due to lack of a SPEM cell subpopulation responsible for metaplasia progression and fibroblast recruitment to gland bases. Instead, homeostatic gastric cell lineages were repopulated in the glands. We also identified a DNA topoisomerase II-α-expressing SPEM cell subpopulation that contributes to metaplasia progression, and putative SOX9 downstream genes associated with lineage plasticity. CONCLUSION: These results demonstrate that SOX9 is a master regulator of SPEM cell lineage evolution and metaplasia progression. Therefore, SOX9-mediated SPEM cell plasticity is a central mechanism in carcinogenesis.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Guenther AA, Ruelas A, Caldwell B, et al. SRY-Box 9-Driven Spasmolytic Polypeptide-Expressing Metaplasia Cell Lineage Plasticity Is a Potential Therapeutic Target That Mitigates Risk of Metaplastic Progression to Gastric Cancer. Gastroenterology. 2026. PMID: 42448241. doi:10.1053/j.gastro.2026.06.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。